Cyclosporine for angioimmunoblastic T-cell lymphoma: a literature review

Expert Review of Hematology
Akihiro Ohmoto, Shigeo Fuji

Abstract

Introduction: Angioimmunoblastic T-cell lymphoma (AITL) is a type of peripheral T-cell lymphomas harboring aggressive biological behaviors and presenting unique immunologic hyperactivation. Gene expression profiling has revealed that AITL cells derive from follicular T helper (Tfh) cells. The prognosis is poor under CHOP-like regimen, and salvage chemotherapy is mostly ineffective. Thus, novel therapies are required in patients with AITL. NCCN Guidelines for peripheral T-cell lymphoma refer to cyclosporin (CyA) as one therapeutic option in second- or later lines especially for AITL cases unfeasible for hematopoietic stem-cell transplantation (HSCT). The clinical data of AITL are based on small-scale case series, and prospective trials are scarce.Areas covered: In this article, the authors reviewed published articles or conference abstracts, and extracted total 26 patients with AITL receiving CyA.Expert opinion: The overall response rate in above 26 patients was outstanding (86% in second or later lines), suggesting the utility in heavily treated cases including those who underwent HSCT. Meanwhile, publication bias is the most serious limitation in this literature review. Larger case series or prospective data with CyA alone or ...Continue Reading

References

Jun 1, 1997·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R AdvaniS Horning
Feb 28, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T RüdigerUNKNOWN Non-Hodgkin's Lymphoma Classification Project
Apr 25, 2007·Leukemia & Lymphoma·Ranjana AdvaniSandra J Horning
Dec 8, 2009·Blood·Javeed IqbalUNKNOWN International Peripheral T-Cell Lymphoma Project
Jan 20, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Owen A O'ConnorSteven Horwitz
Oct 12, 2011·Acta Haematologica·Tsutomu KobayashiMasafumi Taniwaki
Jan 25, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bertrand CoiffierSteven Horwitz
Aug 2, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Francesco d'AmoreHelle E Toldbod
Aug 8, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Massimo FedericoJulie M Vose
May 30, 2013·Haematologica·Elena SabattiniStefano A Pileri
Aug 21, 2013·International Journal of Hematology·Hisao NagoshiMasafumi Taniwaki
Dec 10, 2013·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jamil R AzziSamir G Mallat
Dec 19, 2013·Blood·Oreofe OdejideDavid M Weinstock
Jan 15, 2014·Nature Genetics·Mamiko Sakata-YanagimotoShigeru Chiba
Jan 29, 2014·Seminars in Hematology·Kailash MosalpuriaJulie M Vose
Mar 13, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michinori OguraRyuzo Ueda
Feb 17, 2015·Clinical and Experimental Immunology·R De BruyneM Dullaers
Jun 24, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Owen A O'ConnorAndrei Shustov
Jan 25, 2017·Blood·Matthew A Lunning, Julie M Vose
Mar 28, 2017·Hematology/oncology Clinics of North America·Alessandro Broccoli, Pier Luigi Zinzani
Jun 16, 2018·Frontiers in Immunology·Elizabeth F WallinKathryn J Wood
Mar 13, 2019·Journal of Oncology Practice·Alison J Moskowitz

❮ Previous
Next ❯

Citations

Oct 17, 2020·HemaSphere·Emmanuel BachyPier Luigi Zinzani
Jul 3, 2021·Current Treatment Options in Oncology·Kitsada Wudhikarn, N Nora Bennani

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.